Tests nortriptyline and topiramate for Meniere's disease symptoms
Tests two migraine medicines, nortriptyline and topiramate, in adults with Meniere's disease.
Plain-language title generated from the registry record
Registry title: Treatment of Meniere's Disease With Migraine Medications
Key facts
- Where
- Orange, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 85 years old?
Source: NCT05582837, who can take part
Where in United States
- University of California, Irvine Medical Center ENT Clinic (Pavilion 2)Orange, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Irvine
- Trial code
- NCT05582837
- Record updated
- 22 June 2026
- Original description
Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.Read full original descriptionShow less
Treatment of Meniere's Disease With Nortriptyline-Topiramate Stepwise Regimen: A Randomized Double-Blinded Clinical Trial
Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.
Inclusion: Patients with active or frequent Meniere's Disease; Male or female between the ages of 25 to 85 years; Subject must be compliant with the medication and attend study visits; Must be able to read and write in the English language to provide consenting.
Exclusion: All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria; Subjects with history of surgery for Meniere's Disease; Subject with history of an adverse reaction to medication being prescribed; Subject suffers from a medical condition or has history that may be concerning to the investigator's clinical opinion; Pregnancy will result in automatic exclusion from the study. A urine pregnancy test to rule out pregnancy for all women who are of childbearing potential; Subjects with psychosis; Subjects with neurological neoplasm.